

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2005:300304 CAPLUS Full-text

DN 142:367688

TI Use of galanthamine and the derivatives thereof in the production of medicaments for the treatment of postoperative delirium

IN Bodenteich, Angelika; Frantsits, Werner J.; Pirich, Eberhard; Czollner, Laszlo

PA Sanochemia Pharmazeutika A.-G., Austria

SO PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005030332	A2	20050407	WO 2004-AT251	20040712
	WO 2005030332	A3	20050602		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI AT 2003-1538 A 20030929

OS MARPAT 142:367688


AB The invention discloses the use of galanthamine and the cholinergically active derivs. thereof in the production of medicaments for preventive treatment of postoperative delirium and/or subsyndronal postoperative delirium. Galanthamine, the galanthamine derivative (4aS,6R,8aS)-6-hydroxy-3-methoxy-11-methyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef] [2]benzazepinium bromide, and analogous salts, hydrates or solvates are suited for use according to the invention.

IT 273749-95-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (galanthamine and galanthamine derivs. for treatment of postoperative delirium)

RN 273749-95-4 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-1,2,4,4a-tetrahydro-9-methoxy- (9CI) (CA INDEX NAME)



L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2000:383937 CAPLUS Full-text

DN 133:26864

TI Use of galanthamine and galanthamine derivatives for the treatment of acute functional brain damage

IN Mucke, Martin Alois Hermann; Frohlich, Johannes; Jordis, Ulrich

PA Sanochemia Pharmazeutika A.-G., Austria

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032199	A1	20000608	WO 1998-AT291	19981201
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9914300	A1	20000619	AU 1999-14300	19981201
PRAI	WO 1998-AT291	A	19981201		


AB The invention relates to the use of galanthamine and analogs or acidic addition salts thereof in the production of medicaments for treating states arising from cerebrovascular accidents or closed focal craniocerebral traumas or whiplash injuries.

IT 273749-95-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (galanthamine and derivs. for treatment of acute functional brain damage)


RN 273749-95-4 CAPLUS

CN 3H,6H-5,10b-Ethanophenanthridine-3,10-diol, 7-bromo-1,2,4,4a-tetrahydro-9-methoxy- (9CI) (CA INDEX NAME)




RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1986:618421 CAPLUS Full-text
 DN 105:218421
 TI Clastogenic effect of hippeastidine (HIPP) (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine)
 AU Alarcon, M.; Cea, G.; Weigert, G.
 CS Fac. Biol. Sci. Nat. Resour., Univ. Concepcion, Concepcion, Chile
 SO Bulletin of Environmental Contamination and Toxicology (1986), 37(4), 508-12
 CODEN: BECTA6; ISSN: 0007-4861
 DT Journal
 LA English
 GI




AB In a screening of chilean plants for anticancer activity, a number of alkaloids were isolated from *Hippeastrum ananuca* (Amaryllidaceae). HIPP (I) [66276-51-5] is the 1 that has been shown to exhibit the major antineoplastic activity as tested in KB cells (a human transformed nasopharyngeal cell line) showing an ED50 = 0.270 µg/mL, the dosage required to inhibit by 50% the growth of a cell population.
 IT 66276-51-5
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antineoplastic activity of, in KB cells)
 RN 66276-51-5 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3α,4aβ,5α,10bα)]- (9CI) (CA INDEX NAME)




L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:527844 CAPLUS Full-text
 DN 97:127844
 TI Hippeastidine, C₁₇H₂₃O₄N
 AU Watson, William H.; Zabel, Volker; Silva, Mario; Pacheco, Patricia
 CS Dep. Chem., Texas Christian Univ., Fort Worth, TX, 76129, USA
 SO Crystal Structure Communications (1982), 11(1), 157-62
 CODEN: CSCMCS; ISSN: 0302-1742
 DT Journal
 LA English
 AB The crystal structure of hippeastidine (1,2,3,4,4a,6-hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-ethanophenanthridine) was determined the ring conformations were described.
 IT 81904-08-7
 RL: PRP (Properties)
 (crystal structure of)
 RN 81904-08-7 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridine-3,10-diol, 2,3,4,4a-tetrahydro-8,9-dimethoxy-, [3R-(3 α ,4 α β ,5 α ,10 α)]- (9CI) (CA INDEX NAME)




L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1982:214311 CAPLUS Full-text
 DN 96:214311
 TI Chemical study of Chilean Amaryllidaceae. II. New alkaloids from
 Hippeastrum ananuca Phil
 AU Pacheco, Patricia Del C.; Silva, Mario J.; Sammes, Peter G.; Watson,
 William H.
 CS Fac. Cienc. Biol. Recursos Nat., Univ. Concepcion, Concepcion, Chile
 SO Boletin de la Sociedad Chilena de Quimica (1982), 27(2), 289-90
 CODEN: BOCQAX; ISSN: 0366-1644
 DT Journal
 LA Spanish
 GI




AB I, m. 175°, and hemanthamine, m. 205°, were isolated from H. ananuca bulbs,
 and identified by UV, IR, and H⁺-NMR spectroscopy.
 IT 81904-08-7
 RL: BIOL (Biological study)
 (of Hippeastrum ananuca bulb)
 RN 81904-08-7 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridine-3,10-diol, 2,3,4,4a-tetrahydro-8,9-
 dimethoxy-, [3R-(3 α ,4 α β ,5 α ,10 β α)]- (9CI) (CA INDEX
 NAME)



L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1978:503746 CAPLUS Full-text
 DN 89:103746
 TI Alkaloids of Chilean Amaryllidaceae. I. Hippeastidine and
 epi-homolycorine, two novel alkaloids
 AU Pacheco, P.; Silva, M.; Steglich, W.; Watson, W. H.
 CS Dep. Bot., Univ. Concepcion, Concepcion, Chile
 SO Revista Latinoamericana de Quimica (1978), 9(1), 28-32 Published in:
 Rev. Latinoamer. Quim. 8(4)
 CODEN: RLAQA8; ISSN: 0370-5943
 DT Journal
 LA English
 GI




AB Lycorine, homolycorine, maritidine, hippeastidine (I), and epihomolycorine (II) were isolated from *Hippeastrum ananuca* bulbs. The total alkaloid extract was separated into 4 fractions, each of which showed antitumor activity in KB assay. The structures of I and II were assigned from spectral and x-ray diffraction data.
 IT 66276-51-5
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (of *Hippeastrum ananuca*)
 RN 66276-51-5 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3 α ,4 α β ,5 α ,10 β α)]- (9CI) (CA INDEX NAME)



IT 66322-24-5P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 66322-24-5 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-trimethoxy-, [3R-(3 α ,4 α β ,5 α ,10 β α)]-, compd. with 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 66276-51-5
 CMF C18 H25 N O4



CM 2

CRN 88-89-1


CMF C6 H3 N3 O7



L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 AN 1978:136819 CAPLUS Full-text
 DN 88:136819
 TI 1,2,3,4,4a,6-Hexahydro-10-hydroxy-3,8,9-trimethoxy-5,10b-
 ethanophenanthridinium picrate
 AU Watson, William H.; Taira, Zenei; Silva, Mario; Pacheco, Patricia
 CS Dep. Chem., Texas Christian Univ., Fort Worth, TX, USA
 SO Crystal Structure Communications (1977), 6(4), 797-801
 CODEN: CSCMCS; ISSN: 0302-1742
 DT Journal
 LA English
 AB The crystal structure of the title compound (hippeastidine picrate) was
 determined The conformation was discussed.
 IT 66322-24-5
 RL: PRP (Properties)
 (crystal structure of)
 RN 66322-24-5 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-
 trimethoxy-, [3R-(3 α ,4 α β ,5 α ,10 β α)]-, compd. with
 2,4,6-trinitrophenol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 66276-51-5
 CMF C18 H25 N O4




CM 2

CRN 88-89-1
 CMF C6 H3 N3 O7




IT 66276-51-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 66276-51-5 CAPLUS
 CN 1H,6H-5,10b-Ethanophenanthridin-10-ol, 2,3,4,4a-tetrahydro-3,8,9-
 trimethoxy-, [3R-(3 α ,4 α β ,5 α ,10 β α)]- (9CI) (CA
 INDEX NAME)




L10 ANSWER 1 OF 1 MARPAT COPYRIGHT 2005 ACS on STN
 AN 128:13368 MARPAT Full-text
 TI New benzazepine derivatives, medicaments containing the same and their use to prepare medicaments
 IN Czollner, Laszlo; Frohlich, Johannes; Jordis, Ulrich; Kuenburg, Bernhard
 PA Sanochemia Ltd., Malta
 SO PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9740049	A1	19971030	WO 1997-AT74	19970421
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AT 9600716	A	19971015	AT 1996-716	19960419
	AT 403803	B	19980525		
	AU 9724985	A1	19971112	AU 1997-24985	19970421
	EP 897387	A1	19990224	EP 1997-916263	19970421
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, FI			
	TW 224595	B1	20041201	TW 1997-86106195	19970509
	NO 9804852	A	19981116	NO 1998-4852	19981016
	US 2003092700	A1	20030515	US 1999-242339	19990211
	US 6638925	B2	20031028		
	US 2004067974	A1	20040408	US 2003-647283	20030826
PRAI	AT 1996-716		19960419		
	WO 1997-AT74		19970421		
	US 1999-242339		19990211		

GI



I




II

AB The synthesis of benzofuro[3a,3,2,ef][2]benzazepines (I) [R1,R2 = H, halo, CN, NC, OH, SH, SO3H, NH2, CF3, (un)substituted alkyl, (un)substituted alkoxy, (un)substituted aryl, (un)substituted aryloxy; R3 = OH, OMe; R4,R5 = H2, O, substituted O, (un)substituted alkyl, (un)substituted aryl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted hydrazone, (un)substituted oxime; X = H2, O] and diazabicyclo[2.2.1]heptanes (II) [R8 = CH2Ph, 4-MeC6H4SO2, H, (un)substituted alkyl, Me3CO2C; R9 = (un)substituted Ph, CH2Ph, CHPh2, Me3CO2C] are described. Thus, I (R1 = Br, R2 = H, R3 = OMe, R4 = OH, R5 = H, R6 = H, X = H2) (III) was prepared by tartrate resolution of (±)-N-demethyl-8-bromogalanthamine. III in in vitro study showed an IC50 of >150 in umol for the inhibition of acetylcholine esterase. Also disclosed are medicaments which contain compds. of formulas (I) and/or (II) and may be

successfully used for treating Alzheimer disease and related demential states,
as well as the Langdon-Down syndrome.

MSTR 2



G1 = CH₂CH₂ (opt. substd.)

G5 = CH₂


Patent location:

claim 2

Note:

additional ring formation specified

=> d l2; d his; log y
L2 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 16:38:26 ON 24 AUG 2005)

FILE 'REGISTRY' ENTERED AT 16:38:38 ON 24 AUG 2005

L1 STRUCTURE UPLOADED
L2 QUE L1
L3 1 S L2
L4 4 S L2 FUL

FILE 'CAPLUS' ENTERED AT 16:39:17 ON 24 AUG 2005

L5 7 S L4

FILE 'BEILSTEIN' ENTERED AT 16:39:55 ON 24 AUG 2005

L6 1 S L2 FUL
L7 0 S L6 NOT L5

FILE 'MARPAT' ENTERED AT 16:40:26 ON 24 AUG 2005

L8 0 S L2
L9 1 S L2 FUL
L10 1 S L9 NOT L5

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	118.15	314.86
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.68	-5.79

STN INTERNATIONAL LOGOFF AT 16:41:12 ON 24 AUG 2005